$PPCBSep 16, 2026, 8:42 AM ETAI processed
Propanc (PPCB) pitches preclinical PRP EMT-reversal as complement to RAS inhibitors, plans Phase 1b Feb 2027
AI Summary
Propanc (PPCB) published a comparative analysis arguing its lead candidate PRP — an IV trypsinogen/chymotrypsinogen proenzyme combo that reverses EMT, depletes cancer stem cells and remodels the tumor microenvironment — could complement RAS inhibitors (Revolution’s daraxonrasib, Erasca’s ERAS-0015) by targeting residual mesenchymal/stem-like cells that drive resistance and metastasis. PRP efficacy cited is preclinical (orthotopic and PDX PDAC models: >90% tumor-growth inhibition, marked metastasis reduction, >2.5× median OS) and Propanc plans a multicenter open-label Phase 1b first-in-human study in Feb 2027 for up to 50 advanced solid-tumor patients; the company emphasized comparisons are directional and not head-to-head.
Positives
- Preclinical PDAC models showed >90% tumor-growth inhibition, marked metastasis reduction, and >2.5× median overall survival versus controls
- PRP targets EMT, cancer stem cells, and fibrotic tumor microenvironment — a mechanism orthogonal to RAS inhibition and not restricted to RAS genotype
- Company plans a multicenter Phase 1b first-in-human study in Feb 2027 (up to 50 patients, weekly IV dosing with expansion cohorts)
Negatives
- All efficacy data for PRP cited are preclinical; no human efficacy data yet
- Comparisons to daraxonrasib and ERAS-0015 are cross-modality and not head-to-head; those RAS programs have clinical/approved human data (daraxonrasib FDA-approved Aug 2026)
- Propanc is not announcing any partnerships with Revolution Medicines or Erasca — development/commercial execution remains solo for now